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Abstract
Background: Anaemia and iron deficiency are common complications following post-bariatric abdominoplasty.
Given the low oral absorbability of iron resulting from bariatric surgery, it has been hypothesised that postoperative
intravenously administered iron supplementation could be used to treat anaemia and to prevent the development
of iron deficiency in these patients.
Methods/Design: In this multicentre open-label randomised clinical trial, 56 adult women undergoing post-bariatric
anchor-line abdominoplasty will be allocated at a ratio of 1:1 for postoperative supplementation with two
intravenously administered applications of 200 mg of iron saccharate or postoperative supplementation with
100 mg of iron polymaltose complex administered orally, twice a day for 8 weeks. The primary outcome is the
difference in mean haemoglobin levels between the two groups at eight postoperative weeks. Secondary
outcomes evaluated at one, four and eight postoperative weeks include iron profile, reticulocyte count, overall quality
of life measured using the Short-Form 36 Health Survey (SF-36) questionnaire, fatigue measured using the Functional
Assessment of Chronic Illness Therapy – Fatigue (FACIT-F), adverse effects and postoperative complications.
Discussion: This randomised clinical trial aims to evaluate the haematopoietic effectiveness of intravenously
administered iron supplementation in patients undergoing post-bariatric abdominoplasty. A more effective
recovery of haemoglobin levels could help improve the patients’ quality of life and could provide an improved
haematological status in preparation for the subsequent and frequent plastic surgeries these patients undergo.
Trial registration: Clinicaltrials.gov Identifier: NCT01857011 (8 May 2013), Universal Trial Number U111-1169-6223,
Brazilian Clinical Trials Registry (REBEC): RBR-2JGRKQ.
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Background
The increasing prevalence of overweight and obesity in
many countries has been described as a global pandemic.
The number of overweight and obese individuals has in-
creased from 857 million in 1980 to 2.1 billion world-
wide in 2013 [1]. The proportion of adults with body
mass indexes (BMIs) above 25 kg/m2 has increased be-
tween 1980 and 2013 from 28.8 to 36.9 % in men and
from 29.8 to 38 % in women [1]. Obesity is associated
with increased risk of type 2 diabetes, hypertension, dys-
lipidaemia, cardiovascular diseases, some types of cancer
and mortality [2]. Overweight and obesity were esti-
mated to have caused 3 to 4 million deaths worldwide in
2010, constituting the sixth most important risk factor
for disease development worldwide [3].
Treatment options for obesity include different non-
surgical treatments and bariatric surgery. Compared to
non-surgical treatment, bariatric surgery results in
greater weight loss and an increase in the remission rate
of type 2 diabetes and metabolic syndrome [2]. However,
even though patients undergoing bariatric surgery suc-
cessfully lose weight, 96 % of patients develop a number
of body-contouring deformities caused by excess skin
and residual fat deposits [4, 5].
In addition to causing intertrigo and hygiene and mo-
bility difficulties, skin deformities have the potential to
affect body image, self-esteem and quality of life [6]. Of
the body regions that develop deformities, patients tend
to complain the most about the abdomen [7]. After sig-
nificant weight loss, 75 % of female patients wish to per-
form body-contouring surgery [5, 8].
However, post-bariatric patients are 60–87 % more
susceptible to complications associated with body-
contouring surgery compared to non-bariatric patients
[9]. Dietary deficiencies are common, with 51.3 % of pa-
tients developing iron deficiency and a 36 % prevalence
of anaemia [10, 11]. The primary causes of these condi-
tions are reduction in iron intake, gastric acid secretion
and contact of food with the iron absorption areas of the
duodenal and jejunal segments separated from the
gastrointestinal tract as a result of bariatric surgery [12].
During body-contouring surgery, such as post-bariatric
abdominoplasty, large areas of subcutaneous tissue and
highly vascularised skin are removed and may result in
considerable blood loss. Two months after surgery, pa-
tients normally still have not returned to preoperative
haemoglobin (Hb) levels, and 45 % develop severe iron
deficiency [13].
Anaemia is the second most common complication
during the postoperative period following post-bariatric
abdominoplasty, [7] and these patients have a higher
indication for blood transfusion [14]. However, obser-
vational studies have found an association between
blood transfusion and higher comorbidity and mortality
[15–17], and in patients undergoing post-bariatric
abdominoplasty, transfusions are associated with a two-fold
higher complication rate and longer hospital stays [18].
Moreover, in surgical patients, even low levels of anaemia
have been associated with adverse outcomes [19–22]. The
recovery of Hb levels is considered an important factor in
the postoperative recovery of patients [23], especially in
post-bariatric patients, because they are often subjected to
additional surgical procedures to treat breast, thigh and
arm deformities over relatively short periods of time [24].
In addition, several studies have found that iron deficiency,
even in non-anaemic patients, can cause symptoms of
fatigue; correcting this deficiency helps improve this symp-
tom [25–27].
Iron supplementation can be administered either orally
or parenterally; however, intravenous administration is
five-fold more effective in inducing an erythropoietic re-
sponse after significant blood loss [28]. In addition, or-
ally administered iron can induce side effects such as
gastrointestinal symptoms, jeopardising adherence to
treatment [29]. Moreover, adverse effects caused by the
use of intravenously administered iron, with the excep-
tion of high-molecular-weight iron dextran, are rare
[30]. Observational studies on orthopaedic surgery [31],
digestive tract surgery [32], postpartum haemorrhage
[33] and renal transplantation [34, 35] have demon-
strated the efficacy of intravenously administered iron in
optimising the recovery of Hb levels.
However, a narrative review analysed the results of
four randomised controlled trials that evaluated the im-
pact of the use of intravenously administered iron on the
perioperative status of cardiac and orthopaedic surgical
patients and found that there were no benefits in the re-
covery of Hb levels or reductions in the number of
blood transfusions [36]. In turn, a systematic review
evaluated the effects of iron in anaemic patients without
chronic kidney disease and observed higher Hb levels
with intravenous administration of iron compared to
oral administration, but without clinical benefit in terms
of reducing blood transfusions or improving quality of
life [37]. None of these reviews included patients under-
going post-bariatric surgery. Due to the difficulty in ab-
sorbing iron orally and their low levels of stored iron
[10], there is the possibility that intravenously adminis-
tered iron supplementation can result in a better recov-
ery of Hb levels, a decrease in iron deficiency and,
consequently, improvements in the patients’ quality of
life [13, 38–40].
Objectives
Primary objective
To assess whether iron saccharate supplementation
intravenously administered in two 200-mg doses during
the perioperative period of post-bariatric anchor-line
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abdominoplasty results in an increase in Hb levels in the
eighth postoperative week (study group) compared to or-
ally administered iron supplementation (control group).
Secondary objectives
To investigate whether the use of intravenously adminis-
tered iron has beneficial effects on other haematological
variables, iron profile, transfusion rate, quality of life and
clinical outcomes.
Methods/Design
Trial design
This is a parallel, superiority, randomised controlled
clinical trial with an allocation ratio of 1:1 (Table 1).
Research ethics approval
This protocol was approved by the Research Ethics
Committee of The Federal University of São Paulo (CEP
UNIFESP) and is registered on the Brazil Platform under
Presentation Certificate for Ethics Assessment (Certificado
de Apresentação para Apreciação Ética – CAAE) number
11904213.3.1001.5505.
Consent
The relevant information from this study will be pro-
vided to all patients in an understandable way. Patients
will have the opportunity to have their questions an-
swered and will provide their consent by signing the free
and informed consent form.
Methods: participants, interventions and outcomes
Study setting
The study is being conducted in Brazil, in the urban area
of São Paulo city in two hospitals: Hospital São Paulo
and Hospital do Servidor Público Estadual (State’s Civil
Servants’ Hospital).
Eligibility criteria
Patients who meet the inclusion and non-inclusion cri-
teria, and provide their consent by signing an informed
consent form, are eligible to the study.
Inclusion criteria
Women, between 18 and 55 years of age, formerly obese
patients treated with bariatric surgery using the vertical
banded gastroplasty technique with Roux-en-Y gastric by-
pass by laparotomy, grade III deformity of the abdominal
wall using the Pittsburgh rating scale [41], pre-bariatric
BMI between 35 and 70 kg/m2 and post-bariatric BMI
below 32 kg/m2 with stabilised weight loss for at least
6 months.
Non-inclusion criteria
Illiteracy, tobacco use, cholelithiasis shown on ultra-
sound, uncontrolled systemic diseases, bone marrow dis-
eases, haematological disorders, kidney or liver failure,
acute infection, use of intravenously administered iron
in the previous 3 months, prior anaphylactoid reaction
with the use of intravenously administered iron, Hb levels
less than 11.5 g/dL, ferritin levels less than 11 ng/mL or
greater than 100 ng/mL, transferrin saturation index (TSI)
greater than 50 % or less than 16 %, vitamin B12 levels less
than 210 pg/mL, folic acid levels less than 3.3 ng/mL, al-
bumin levels less than 3 g/dL, ultrasensitive C-reactive
protein (CRP) levels greater than 5 mg/L, and mean
corpuscular volume less than 80 fL.
Exclusion criteria
The exclusion criteria include major intraoperative
haemorrhaging with hemodynamic instability or haema-
toma formation requiring drainage in the operating
room.
Interventions
Patients in the study and control groups undergo a
mixed-type abdominoplasty, also known as anchor-line
abdominoplasty, based on a previously published pro-
cedure [42], under general anaesthesia, coordinated by
the same surgeon for all the operations.
Both the study group and the control group are
instructed to maintain, postoperatively, routine vitamin
and mineral supplementation for post-bariatric patients,
ensuring that the supplement Materna® (Wyeth Laboratory,
Markham, ON, Canada), which contains 60 mg of iron,
1 mg of folic acid and 12 μg of vitamin B12, among other
elements, is taken daily after breakfast.
Patients in the study group receive intravenously, dur-
ing the immediate postoperative period, 200 mg of ferric
hydroxide saccharate (Takeda Pharma Ltd., Berlin,
Germany) diluted in 200 mL of saline over 60 minutes.
The same dose is administered on the first postoperative
day post-bariatric abdominoplasty, totalling 400 mg of
intravenously administered iron supplementation for
each patient in the study group. The iron is administered
by the nursing team as specifically recommended for the
administration of intravenous iron, with monitoring of
vital signs and possible adverse reactions [43].
Patients in the control group receive an additional
postoperative orally administered supplementation of
iron through the ingestion of one tablet of 330 mg of
iron (III)-hydroxide polymaltose complex (equivalent to
100 mg of elemental iron) after lunch and another after
dinner. Patients in the control group are instructed to
maintain this additional orally administered iron supple-
mentation during the 8-week follow-up period (Fig. 1).
Montano-Pedroso et al. Trials  (2016) 17:196 Page 3 of 11
Interventions – modifications
Gastrointestinal upset
Iron polymaltose has a lower incidence of adverse
effects than other ferrous salts [44]. However, pa-
tients are instructed to take the iron orally after
meals to minimise gastrointestinal effects of the
medication. Patients who report gastrointestinal
symptoms may reduce the supplement dose to one
tablet per day.
Allergic reactions
Allergic reactions to the use of intravenously administered
iron are rare, and severe adverse effects have been reported
only at doses above 400 mg [30]. In the case of an allergic
Table 1 World Health Organisation (WHO) trial registration data set
Primary registry and trial identifying number NCT01857011
Date of registration in primary registry 8 May 2013
Secondary identifying numbers U1111-1169-6223, Brazilian Clinical Trials Registry (REBEC): RBR-2JGRKQ
Source of monetary or material support São Paulo Research Foundation (Fundação de Amparo à Pesquisa do Estado de São Paulo – FAPESP),
grant #2014/07710-6
Primary sponsor Federal University of São Paulo
Secondary sponsor Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE)
Contact for public queries Juan Carlos Montano Pedroso (juancmontano@gmail.com)
Contact for scientific queries Juan Carlos Montano Pedroso (juancmontano@gmail.com0
Public title Iron Supplementation for the Treatment of Acute Anaemia After Postbariatric Tummy Tuck
Scientific title Postoperative intravenously administered iron sucrose 200 mg administered twice or
postoperative orally administered iron for the treatment of post-bariatric abdominoplasty
anaemia (ISAPA): a randomised controlled trial
Countries of recruitment Brazil
Health conditions or problems studied Postoperative anaemia, iron deficiency
Interventions Study group: administration of 200 mg of iron sulphate intravenously after post-bariatric
abdominoplasty, immediately after the operation and on the first postoperative day
Control group: ferrous sulphate supplementation orally administered postoperatively at
a dose of 1 tablet of 100 mg 12/12 h for 8 weeks.
Key inclusion and exclusion criteria Inclusion criteria: women; 18 to 55 years old; previous bariatric surgery; body mass index (BMI) less
than 32 kg/m2; stability of weight loss for at least 6 months
Exclusion criteria: smoking; cholelithiasis demonstrated by ultrasound; uncontrolled systemic
diseases; bone marrow diseases; haematological disorders; presence of renal or hepatic
insufficiency; acute infection; prior use of intravenously administered iron in the last 3 months;
haemoglobin level less than 11.5 g/dL; ferritin level less than 11 ng/mL or greater than 100 ng/mL;
transferrin saturation index below 20 % or exceeding 50 %; vitamin B12 level less than 210 pg/mL;
folic acid level less than 3.3 ng/mL; albumin level less than 3 g/dL; C-reactive protein greater than
5 mg/L; mean corpuscular volume less than 80 fL
Study type Interventional
Allocation: randomised
Masking: unblinded
Assignment: parallel
Purpose: treatment
Phase: not applicable
Date of first enrolment April 2014
Target sample size 56
Recruitment status Recruiting
Primary outcome Haemoglobin level increase in the eighth week of postoperative abdominoplasty after bariatric
surgery, measured by automated haematology counter in g/dL
Key secondary outcomes Presence of iron deficiency assessed by serum ferritin, postoperative haemoglobin levels, fatigue
measured by the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) questionnaire,
quality of life measured by the Short-Form 36 Health Survey (SF-36), adverse events, surgical
complications. Timepoints: 1, 4 and 8 postoperative weeks
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reaction, the medication is suspended immediately, and the
event is reported as an adverse event.
Interventions – adherence
Adherence reminder sessions
Face-to-face reminder sessions as to the importance of
treatment adherence occur the day before surgery and at
each postoperative return appointment [45]. Such ses-
sions include:
 The importance of following medical
recommendations on the use of medications. In
addition, to facilitate adherence, recommendations
on the ingestion of medications are associated with
the patients’ daily activities, specifically their meals
 Clear instructions, in writing and verbally, are
provided for all prescriptions and, after asking
whether the patient has any questions, the patient is
asked to repeat the instructions in their own words
Adherence assessments
Two indirect methods to measure patient adherence are
used: the Morisky-Green test (MGT) [46–48] and the
Haynes-Sackett test [49, 50]. The MGT consists of four
questions: (1) ‘Do you ever forget to take your medi-
cine?’, (2) ‘Are you careless at times about taking your
medicine?’, (3) ‘When you feel better, do you sometimes
stop taking the medicine?’, (4) ‘Sometimes, if you feel
worse when you take the medicine, do you stop taking
it?’An affirmative response to any one of these questions
classifies the individual as non-adherent. The Haynes-
Sackett test consists of the following statement and
question: ‘Many people have some kind of problem with
taking their medication. In the last 30 days, have you
had difficulties with taking your medication?’An affirma-
tive response classifies the individual as non-adherent.
Both methods are used during each patient’s return visit
to quantify adherence to treatment.
Interventions – concomitant care
All patients are discharged on the second postoperative
day and provided with prescriptions of antibiotics (cefa-
droxil, 500 mg orally 12/12 h), analgesics (dipyrone,
1000 mg orally 6/6 h) and anti-inflammatory drugs
(celecoxib, 200 mg orally 12/12 h) for use during the
first postoperative week. Suction drains are removed
when drainage is less than 50 mL in 24 hours. A restrict-
ive practice was adopted for blood transfusions, in which
none of the patients receive blood transfusion while
their Hb levels remain above 7 g/dL [51].
Patients receive a list with nutritional guidelines that
advise them to eat six times per day, chew their food
well, avoid fatty foods and sweets and include fruits and
vegetables in their diet. The use of other food or vitamin
supplements is not permitted other than those recom-
mended by the study during follow-up.
Fig. 1 Trial flow diagram
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Outcomes
Primary outcome measures
The primary outcome is the detection of a minimum dif-
ference of 1.5 g/dL in the final mean values of Hb levels
at the eighth postoperative week between the study and
control groups.
Secondary outcome measures
Laboratory variables
In addition to Hb levels, haematocrit levels, ferritin
levels, the TSI, the reticulocyte count and CRP levels are
measured preoperatively, the day before surgery and at
one, four and eight postoperative weeks. At the end of
follow-up (8 weeks), the proportions of patients with an-
aemia (Hb below 12 g/dL) and without anaemia (Hb
above 12 g/dL) and with iron deficiency (ferritin below
30 ng/mL) and without iron deficiency (ferritin above
30 ng/mL) are evaluated, together with the percentages
of success in the full recovery of preoperative Hb levels
among the patients in the study and control groups.
Laboratory tests are conducted in the Hospital do Servidor
Estadual and Hospital São Paulo laboratories, following the
recommendations of the Brazilian Society of Clinical Path-
ology and Laboratory Medicine (Sociedade Brasileira de
Patologia Clínica e Medicina Laboratorial – SBPC/ML). All
instruments used in this study were subjected to internal
(the manufacturer) and external controls through the
Program of Excellence for Medical Laboratories (Programa
de Excelência para Laboratórios Médicos) associated with
SBPC/ML.
Quality of life
Quality of life is assessed using a generic questionnaire
(Short-Form 36 Health Survey (SF-36)) [52] and a spe-
cific questionnaire to assess fatigue and other anaemia-
related symptoms (Functional Assessment of Chronic
Illness Therapy – Fatigue (FACIT-F)) [53], both trans-
lated and validated for Portuguese, applied using an
assisted self-administered questionnaire the day before
surgery and then at one, four and eight postoperative
weeks.
Adverse effects
Adverse effects will be estimated by measuring the dif-
ferences between the two groups in regards to the pro-
portions of mild (grades 1 and 2) and severe (grade 3, 4
and 5) adverse effects, which are possibly, probably, or
definitely related to the use of iron supplementation
during the follow-up period. Version 4 of Common
Terminology Criteria for Adverse Events (CTAE v4.0)
[54] will be used to grade adverse effects. The following
adverse effects will be considered mild: transitory de-
velopment of a skin rash, itching, tachycardia, tremor,
dyspepsia, constipation, and nausea with improvement
after discontinuation of medication or of symptomatic
treatment. The following adverse effects will be consid-
ered severe: the maintenance of symptoms even after
discontinuing the medication and treatment, need for
hospitalisation, bronchospasm, anaphylactic shock and
death. At each visit, patients will be asked about ad-
verse events that have manifested since their previous
visit. A standardised list containing the most common
adverse effects of iron supplementation will be used.
Cases where there is a need to definitively discontinue
use of the medication will be considered treatment
failures.
Surgical complications
Postoperative complications, divided into systemic and
local, are evaluated over the 8 weeks of postoperative
follow-up, and their percentages are compared be-
tween the study and control groups. The following
complications are considered systemic: the need for
hospital readmission, postoperative blood loss with an
indication for blood transfusion, deep vein thrombosis
(diagnosed by ultrasound examination), pulmonary
embolism (diagnosed using an angiographic examin-
ation) and death.
The following complications are considered local: ser-
oma (accumulation of serous subcutaneous fluid evident
upon physical examination after removing the drain and
following at least one aspiration); haematoma (accumu-
lation of haematic subcutaneous fluid evident upon
physical examination after removing the drain and fol-
lowing at least one aspiration); wound infection (based
on the definition established by the Centers for Disease
Control and Prevention (CDC) [55]); wound dehiscence
(defined as separation of the wound margins requiring
medical or surgical treatment [56]); and necrosis
(defined by the presence of devitalised tissue that ex-
tends through the full thickness of the skin, requiring
surgical debridement).
Dietary survey
To determine whether there are differences in the iron
dietary intake levels between the two groups, a dietary
survey is conducted. At the eighth postoperative week,
patients answer a 24-hour diet recall survey in which
they report all food and drinks consumed during the
previous day, from breakfast to dinner [57]. The recall is
administered by a professional dietician following the
recommendations of the Nordic Cooperation Group of
Dietary Researchers [58]. NutWin version 3.0 software,
developed and validated by the Federal University of São
Paulo (Universidade Federal de São Paulo), is used to
calculate dietary iron intake [59].
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Menstruation
Because prolonged menstrual bleeding lasting more than
7 days can have an impact on Hb levels [60], all patients
are asked during the follow-up period whether they have
had menstrual bleeding lasting for more than 7 days.
Sample size
A sample size of 56 patients (28 per group) was calcu-
lated, assuming an 80 % statistical power to detect a
minimum difference in Hb levels of 1.5 g/dL (the pri-
mary outcome), considering a standard deviation for Hb
levels of 1.84 [61], a two-tailed significance level of 0.05
and a patient loss to follow-up of 10 %.
The need for postoperative follow-up assessments of
participants, the relatively brief 8-week follow-up
period, the flexibility to decrease the iron oral dose to
one tablet daily for patients reporting gastrointestinal
symptoms, and reminder sessions for treatment adherence
might reduce participant attrition and, consequently, the
attrition bias.
Recruitment
Patients are recruited from the post-bariatric plastic sur-
gery outpatient clinics of Hospital do Servidor Estadual
and Hospital São Paulo via local advertisements. Patients
on hospital waiting lists are also identified. Both hospi-
tals have active bariatric surgery services that regularly
refer patients to the post-bariatric plastic surgery out-
patient clinic; therefore, we do not expect challenges
regarding patient recruitment.
Methods – assignment of interventions
Allocation – sequence generation
The patients are allocated to the study or control group
at a ratio of 1:1 using a computer-generated randomiser
(http://www.randomization.com) with fixed block sizes.
The block sizes are kept confidential.
Allocation – concealment mechanism
Opaque, sealed, serially numbered envelopes containing
carbon paper and aluminium foil inside are used to
maintain the confidentiality of the random allocation.
The researchers responsible for the recruitment do not
receive any information regarding the groups into which
the patients are allocated. The allocation of the study
participants was defined using a computer-generated
random sequence. Confidentiality of the block size and
blinding patient allocation using a series of opaque,
sealed, and numbered envelopes were used to reduce
selection bias.
Allocation: implementation
A surgical team member who did not participate in the
recruitment of patients generated the allocation
sequence and maintained the allocation concealment.
The researchers responsible for recruitment did not re-
ceive any information regarding the patient allocation
groups. The sequentially numbered envelopes remained
stored with the surgical team member throughout the
study. Prior to the post-bariatric abdominoplasty sur-
gery, the surgeon wrote the name of the patient on the
envelope that corresponded to the numerical sequence
of the research. At the end of the surgery, the envelope
was opened, revealing the research group to which the
patient belonged.
Blinding
Due to the nature of the intervention (orally adminis-
tered iron supplements result in blackening of the stool
[62], facilitating the identification of the allocation
group), we chose not to blind the patients or researchers
to the allocation group. However, the surgeon who eval-
uates the incidence of local complications is blinded to
the allocation group. In addition, the patients are not in-
formed about the outcome of their laboratory tests to
prevent the knowledge of their test results from influen-
cing their responses on the quality of life questionnaires
[63]. The use of an objective laboratory measurement as
the primary endpoint (Hb level) also reduces detection
bias.
Although unmasked clinical trials are subject to per-
formance bias, the disclosure of allocation concealment
at the end of the surgery reduces the possibility of surgi-
cal team performance bias during surgery. In addition,
both the recommendation to use the same vitamin and
mineral supplementation and the written supply of the
same nutritional guidelines for all participants aim to re-
duce performance bias over the postoperative follow-up
period.
Methods – data collection, management, and analysis
Data collection methods
Researchers collect patient demographic data using a
standardised form for all study patients.
Data collection methods – retention
The night before each outpatient visit, patients are con-
tacted by telephone and reminded of the importance of
collecting blood for laboratory tests, completing the
quality of life questionnaires, and the medical evaluation.
Data management
All data collected during the study are entered into two
separate spreadsheets at different times. The two spread-
sheets are then compared with each other to ensure the
accuracy of the data collected [64].
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Statistical methods
Statistical methods – outcomes
The data will be entered into the statistical software
Statistical Package for the Social Sciences (SPSS), version
17.0, and initially evaluated descriptively using summary
measures (means, standard deviations, minima, maxima,
and quartiles). To guarantee reliability and avoid select-
ive outcome reporting, a fully specified statistical ana-
lysis plan will be written before unmasking.
To analyse the behaviour of variables for quality of life,
Hb level, reticulocyte count, iron profile and CRP level
at different times, a repeated measure analysis of vari-
ance (ANOVA) will be employed. This model will pre-
suppose the normality of the data tested in the residuals
(difference between the observed and estimated value) of
the fitted model using the Kolmogorov-Smirnov test.
To determine the presence of an interaction between
group and time, the means of the variables between
groups will be compared at each time-point using Stu-
dent’s t test for independent samples, and means be-
tween different time-points for each group will be
compared using Student’s t test for paired samples.
For those variables in which there is a lack of normal-
ity in the data, non-parametric Mann-Whitney tests will
be performed to compare the differences between
groups at each time-point, and the Wilcoxon test will be
used to compare patterns over time for each group.
Bonferroni correction will be used for these tests to en-
sure an overall significance level of 5 %.
Statistical methods: additional analyses
Adjusted analyses
The final mean Hb levels in the eighth postoperative
week (primary outcome) will be adjusted for baseline Hb
level, ferritin levels, and TSI via an analysis of covariance
(ANCOVA). Both the adjusted and unadjusted analyses
will be reported in the final publication.
Statistical methods – analysis population and missing
data
Data analysis will be performed based on the original al-
location of all patients as defined by randomisation, re-
gardless of the degree of adherence to the protocol
(intention-to-treat principle).
With respect to missing data, the amount thereof,
their patterns and variables associated with omission will
define the most appropriate technique to be used in the
processing of such data, whether in the primary analysis
or the sensitivity analysis. For primary analyses, methods
will be used that make use of all available data, such as
multiple imputations. To reduce the presence of incom-
plete data and attrition bias, the need to discontinue the
allocated treatment will be considered as treatment
failure.
Dissemination
Protocol amendments
Any changes to the protocol that might affect the study,
the potential benefits for patients, or their safety (includ-
ing changes to the study objectives, design, patient
population, sample size, study procedures, or significant
administrative aspects) will require a formal amendment
to the protocol. These changes will be agreed upon
among the researchers and will require approval from
the Research Ethics Committee before implementation.
Confidentiality
All participant information will be kept in password-
protected files, and the identifiable data will be replaced
by codes.
Access to data
All of the researchers involved in this study will have ac-
cess to all of the collected data.
Dissemination policy – authorship
The criteria for authorship of this protocol followed the
guidelines established by the International Committee of
Medical Journal Editors [65]. A team of professional
translators was used to translate the text from Portu-
guese into English. The final report will follow the Con-
solidated Standards of Reporting Trials (CONSORT)
2010 guidelines.
Discussion
Anaemia is the second most frequent complication fol-
lowing post-bariatric abdominoplasty [7]. Two months
after surgery, these patients have still not recovered
their preoperative Hb levels, and 45 % develop severe
iron deficiency [13]. However, the recovery of Hb levels
is considered an important factor in postoperative pa-
tient recovery [23]. This aspect becomes even more
relevant in post-bariatric patients, as they often
undergo a series of subsequent surgical procedures to
treat deformities in different regions of the body; thus,
they only have a short time to recover their haemato-
logical parameters [24].
A systematic review concluded that iron supplementa-
tion is effective in promoting an increase in Hb levels
[37]. Although iron supplementation can be adminis-
tered either orally or intravenously, it has been hypothe-
sised that intravenous administration has improved
efficacy in the population of post-bariatric patients given
the difficulties with orally administered iron absorption
in these patients [12]. This randomised clinical trial
protocol was designed to test this hypothesis because no
studies were found in the literature that evaluated the ef-
fect of iron supplementation in a population of patients
undergoing post-bariatric surgery.
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Blinding is commonly used in randomised clinical tri-
als to reduce the risk of bias [66]. However, because or-
ally administered iron supplementation can cause stool
colour changes, the implementation of blinding in this
study was considered to be impractical. In fact, most
published randomised clinical trials evaluating the effect
of iron supplementation in postpartum women were not
blinded [67].
The primary outcome of this study is the detection of
a minimum difference of 1.5 g/dL in the final mean
values of Hb levels at the eighth postoperative week be-
tween the study and control groups. This difference in
Hb levels was established based on the fact that the pa-
tients in the study group receive a total of 400 mg of
intravenously administered iron, and 200 mg of iron is
needed to increase Hb levels by approximately 1 g/dL
[31]. This dose would be sufficient to recover the loss of
approximately 2.1 g/dL of Hb that occurs during this
type of surgery [13]. Because the control patients receive
iron orally and the absorption of iron in these patients is
compromised as a result of bariatric surgery [38], a dif-
ference in Hb levels of 1.5 g/dL between the study and
control groups was considered to be biologically
plausible.
The choice of a laboratory variable as a primary out-
come rather than a more relevant clinical outcome, such
as reduced blood transfusion rate or improved quality of
life, could be considered a limitation of this study [68].
However, because each 1 g/dL increase in Hb increases
the SF-36 vitality score from 1.2 to 7.4 points [69] and
the minimum clinically relevant difference in the SF-36
vitality score is 5 points [70], a difference of 1.5 g/dL in
Hb levels was considered to have the potential to be
clinically relevant. Consequently, the response of Hb
levels to treatment was defined as the primary outcome,
as published in other protocols [71]. The eighth postop-
erative week was determined as the primary time-point
for haemoglobinometric measurements because the
postoperative recovery of Hb levels largely occurs be-
tween 4 and 6 weeks following major surgery [72, 73].
It is unlikely that the use of intravenously administered
iron compared to orally administered iron can signifi-
cantly alter relevant clinical outcomes, such as hospital
readmission or mortality rates. However, there is an in-
creasing recognition of the importance of the benefits of
small interventions in surgical care as opposed to a sin-
gle ‘magical’ intervention to improve outcomes following
surgery [74]. Furthermore, iron supplementation runs
counter to a paradigm shift known as patient blood
management.
Patient blood management has been increasingly ac-
cepted as an effective means of reducing blood transfu-
sion rates and improving postoperative outcomes [75]. It
is defined as the application of evidence-based medical
and surgical concepts aimed at superior clinical out-
comes through the improved utilisation of the patient’s
own blood instead of donor blood. Such management is
intended to maintain the concentration of Hb, to opti-
mise homeostasis and to minimise blood loss. It consists
of three pillars: (1) optimising erythropoiesis, (2) mini-
mising blood loss, and (3) promoting a greater tolerance
to anaemia [76]. Intravenously administered iron supple-
mentation falls under the first pillar. The proposed study
represents a randomised clinical trial designed to assess
the effect of intravenously administered iron supplemen-
tation in treating anaemia following post-bariatric
abdominoplasty.
Trial status
Recruiting. The first patient was randomised in April
2014; by August 2015, 19 patients had undergone
surgery.
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